

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 00455)**

## **COMPLETION OF CONNECTED AND MAJOR TRANSACTION DISPOSAL OF 100% EQUITY INTEREST OF A WHOLLY-OWNED SUBSIDIARY**

References are made to the announcements of Tianda Pharmaceuticals Limited (the "Company") dated 22 February 2019 and 7 May 2019 and the circular of the Company dated 12 April 2019 (the "Circular"), in relation to the disposal of 100% equity interest of a wholly-owned subsidiary of the Company. Unless otherwise specified, capitalised terms used herein shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that the Closing took place on 29 March 2022. As disclosed in the Circular, pursuant to the Agreement, the Consideration for the Target Shares shall be RMB125 million plus the cash at bank of Zhuhai Target as at the Closing Date of RMB13 million, amounting to RMB 138 million in total.

*By order of the Board*  
**Tianda Pharmaceuticals Limited**  
**FANG Wen Quan**  
*Chairman and Managing Director*

Hong Kong, 29 March 2022

*As at the date of this announcement, the executive directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the non-executive directors are Mr. SHEN Bo and Mr. FENG Quanming; and the independent non-executive directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Mr. CHIU Fan Wa.*